EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Future of Precision Oncology

Stuart L Rulten iD, Richard P Grose iD, Susanne A Gatz, J Louise Jones, Angus J M Cameron iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms241612613 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Stuart L Rulten und 4 weiteren Autor:innen. Beteiligte Einrichtung: Prime Omics, Prime Global, Knutsford WA16 8GP, UK. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit wurde bisher 73-mal zitiert (Crossref) und nennt 150 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK, Prime Global.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Our understanding of the molecular mechanisms underlying cancer development and evolution have evolved rapidly over recent years, and the variation from one patient to another is now widely recognized. Consequently, one-size-fits-all approaches to the treatment of cancer have been superseded by precision medicines that target specific disease characteristics, promising maximum clinical efficacy, minimal safety concerns, and reduced economic burden. While precision oncology has been very successful in the treatment of some tumors with specific characteristics, a large number of patients do not yet have access to precision medicines for their disease. The success of next-generation precision oncology depends on the discovery of new actionable disease characteristics, rapid, accurate, and comprehensive diagnosis of complex phenotypes within each patient, novel clinical trial designs with improved response rates, and worldwide access to novel targeted anticancer therapies for all patients. This review outlines some of the current technological trends, and highlights some of the complex multidisciplinary efforts that are underway to ensure that many more patients with cancer will be able to benefit from precision oncology in the near future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsHumansPrecision MedicineMedical OncologyInterdisciplinary StudiesPhenotype

Stichwörter der Autor:innen

genomicsmetabolomicsmicrobiomemolecular profilingprecision oncologyproteomicstranscriptomics

Autor:innen und Institutionen

  • Prime Omics, Prime Global, Knutsford WA16 8GP, UK.
  • Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK.
  • Cancer Research UK Clinical Trials Unit (CRCTU), Institute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.

ORCID-Profile: Stuart L Rulten, Richard P Grose, Angus J M Cameron

Förderung

  • Cancer Research UK
  • Prime Global

Zitieren

APA

Rulten, S. L., Grose, R. P., Gatz, S. A., Jones, J. L., & Cameron, A. J. M. (2023). The Future of Precision Oncology. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241612613

Vancouver

Rulten SL, Grose RP, Gatz SA, Jones JL, Cameron AJM. The Future of Precision Oncology. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241612613

BibTeX
@article{Rulten2023,
  author = {Rulten, Stuart L and Grose, Richard P and Gatz, Susanne A and Jones, J Louise and Cameron, Angus J M},
  title = {The Future of Precision Oncology},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms241612613}
}
Kostenlos starten →